Dr. Rohtash Kumar Joins Veranova as Chief Technology Officer
Wayne, PA – Veranova announced today the appointment of Dr. Rohtash Kumar as the company’s SVP, Development Operations and Chief Technology Officer based in Devens, MA.
Rohtash Kumar brings extensive CDMO experience to his new role. He has previously led technical teams, engaged in the discovery and development of new products for use in clinical trials, and successfully run programs for the commercial supply of APIs in the branded market. Rohtash most recently served as Site Head at Bachem Americas Inc., where he held several positions including Vice President of API Manufacturing. Prior to Bachem, Rohtash worked with Sigma-Aldrich as Manager of R&D and Manufacturing. In the early part of his career, Rohtash worked at Toronto Research Chemicals as a Group Leader, and at Apotex as a Senior Research Chemist.
Rohtash obtained a Ph.D. in Organic Chemistry from Delhi University, India, specializing in Total Synthesis. He also holds an MSc. in Organic Chemistry and an MBA with a focus on Production & Personnel Management from Chaudhary Charan Singh University, India. Following his Ph.D, Rohtash went on to complete postdoctoral work in Medicinal Chemistry at the University of Alberta, Canada, and at the National Research Council of Canada in Organic Chemistry.
“We are excited that Rohtash will join Veranova to help drive and accelerate our development and scale-up activities for our originator customers’ programs and support the continued development of new business and overall growth of Veranova,” said Mike Riley, CEO of Veranova.
About Veranova
Veranova is a global leader in process development and manufacturing of APIs, with a focus on specialty and complex products. Veranova is headquartered in Wayne, PA and has operations in North America, Europe and Asia. For more information, please visit www.veranova.com
Latest articles
-
Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial
-
FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
-
Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY